Welcome to our dedicated page for Prenetics SEC filings (Ticker: PRE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Prenetics Global Limited (NASDAQ: PRE) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as a foreign private issuer. Prenetics files reports with the U.S. Securities and Exchange Commission under the Exchange Act, including Form 20-F for annual reporting and Form 6-K for current reports. These filings document key developments in the company’s health sciences business, its IM8 premium health and longevity brand, and its capital markets activities.
Form 6-K current reports for Prenetics frequently furnish press releases on topics such as quarterly financial results, public offerings of Class A ordinary shares and associated warrants, warrant exchange programs, strategic divestitures, and updates to capital allocation strategy. For example, 6-K filings have incorporated press releases announcing third quarter financial results, the closing of a best efforts public offering, and the cessation of new Bitcoin purchases in favor of focusing capital on IM8.
Filings also disclose capital structure details, including the terms of Class A, Class B, and Class C warrants, placement agency agreements, and warrant agency agreements. These documents provide the legal and economic terms governing warrants, exercise prices, durations, and any forced-redemption features. Investors interested in potential dilution, warrant overhang, and equity-linked instruments can review these filings to understand how Prenetics manages its capital structure.
SEC reports further capture strategic and governance events, such as notices of annual general meetings, incorporation by reference of press releases into registration statements on Form F-3 and Form S-8, and information about principal executive office locations in Charlotte, North Carolina, and Hong Kong. Certain 6-Ks also describe open market share purchases by members of the executive leadership team, offering insight into insider activity and alignment with shareholders.
On Stock Titan, these filings are updated as they are released on EDGAR. AI-powered summaries help explain the significance of complex documents, including annual reports on Form 20-F, quarterly results furnished on Form 6-K, and filings related to offerings and warrant exchanges. Users can quickly see what changed in a filing, how it affects Prenetics’ IM8-focused strategy, and where insider transactions or capital allocation decisions appear in the official record.
By reviewing Prenetics’ SEC filings alongside AI-generated insights, investors can better understand the company’s financial reporting, risk disclosures, capital allocation policies, and structural changes that shape the long-term outlook for PRE and its IM8 health and longevity platform.
Prenetics Global Limited furnished a Form 6-K noting it issued a press release announcing a proposed public offering. The company states that the press release, dated October 24, 2025, is provided as Exhibit 99.1 to this report.
The filing lists the exhibit and includes the company’s authorization by Chief Financial Officer Lo Hoi Chun.
Prenetics Global Limited furnished Amendment No. 1 to Form 6-K, adding its condensed consolidated financial statements for the six months ended June 30, 2025 as Exhibit 99.2. The amendment supplements the September 12, 2025 Form 6-K that included business updates and unaudited Q2 results and does not change other information. This report is incorporated by reference into the company’s Form F-3 and Form S-8 registration statements.
Prenetics Global Limited filed Amendment No. 2 to its Form 6-K to update the risk disclosure tied to its bitcoin treasury strategy. The amendment replaces and supersedes the prior Exhibit 99.1 in an earlier Form 6-K/A, which itself had replaced the original Form 6-K risk factor exhibit. Other disclosures in the earlier Form 6-K and Form 6-K/A remain unchanged. The filing also reiterates that statements about expectations and future performance are forward-looking and subject to significant risks and uncertainties referenced in the company’s Form 20-F and other SEC filings.
On 1 Aug 2025, Prenetics Global Limited (NASDAQ: PRE) reported the results of an Extraordinary General Meeting via Form 6-K. Shareholders approved two resolutions:
- Proposal 1 – Authorised Share Capital Increase: the authorised capital rises from US$50,000 (33.3 m shares) to US$320,000 (213.3 m shares) at the unchanged par value of US$0.0015. This adds 160 m Class A shares, 12 m Class B convertible shares and 8 m undesignated shares. The motion passed with 4,250,875 votes FOR versus 503,820 AGAINST (≈78.7% support).
- Proposal 2 – Administrative Filing Authority: authorises the company’s registered office provider to file the amended charter with Cayman authorities. Passed with 4,744,054 FOR and only 14,922 AGAINST.
No financial results were disclosed. Approval materially expands the company’s capacity to issue new equity, signalling potential future capital raises and possible dilution for existing holders.